Harrow, Inc. (HROW)
Pitch Summary: Harrow is an ophthalmology-focused pharma platform that has leveraged its ImprimisRx compounding footprint (10k+ prescribers) to in-license and scale branded eye-care drugs with low up-front cost and pay-as-you-go royalties. The crown jewels are VEVYE (cyclosporine 0.1% in Novaliq’s SFA vehicle) and IHEEZO (topical ocular anesthetic), both showing rapid adoption with improving access and […]
